FDA Targeting GDUFA Fee Scofflaws Again With Letters
This article was originally published in The Pink Sheet Daily
Executive Summary
Four warning letters this year have gone to companies that owe finished dosage form and active pharmaceutical ingredient facility fees.
You may also be interested in...
User Fee Program Six-Month Metrics
After six months under the new prescription drug, generic drug and biosimilar user fee programs, FDA has shown some progress in collecting the necessary fees and conducting sponsor meetings required under the new programs.
Rare Cancer Development Consortium Moving Toward Target Selection
An upcoming public meeting will include a look at platforms before the first targets are chosen.
Stealth’s Elamipretide Gets US FDA Review, But Same Questions Linger
The Barth Syndrome candidate application will be reviewed by the FDA, but Stealth BioTherapeutics' CEO tells the Pink Sheet that the company still does not have clear guidance on how or whether it should gather additional clinical data.